

Development of a Hypoxia Gene Expression Classifier with Predictive Impact for Hypoxic Modification of Radiotherapy in Head and Neck Cancer

Kasper Toustrup¹, Brita Singers Sørensen¹, Marianne Nordmark¹, Morten Busk¹, Carsten Wiuf², Jan Alsner¹, and Jens Overgaard¹

Abstract

Hypoxia, a common feature of the microenvironment in solid tumors, is associated with resistance to radiotherapy, reduced therapeutic response, and a poorer clinical outcome. In head and neck squamous cell carcinomas (HNSCC), the negative effect of hypoxia on radiotherapy can be counteracted via addition of hypoxic modification to the radiotherapy. To predict which patients harbor hypoxic tumors and would therefore benefit from hypoxic modification, clinically applicable methods for pretherapeutic hypoxic evaluation and categorization are needed. In this study, we developed a hypoxia classifier based on gene expression. Through study of xenograft tumors from human squamous cell carcinoma cell lines, we verified the *in vivo* relevance of previously identified *in vitro* derived hypoxia-induced genes. We then evaluated a training set of 58 hypoxia-evaluated HNSCCs to generate a gene expression classifier containing 15 genes. This 15-gene hypoxia classifier was validated in 323 patients with HNSCC randomized for hypoxic modification or placebo in combination with radiotherapy. Tumors categorized as hypoxic on the basis of the classifier were associated with a significantly poorer clinical outcome than nonhypoxic tumors. This outcome was improved and equalized to the nonhypoxic tumors by addition of hypoxic modification. Thus, findings show that the classifier attained both prognostic and predictive impact, and its pretherapeutic use may provide a method to identify those patients who will benefit from hypoxic modification of radiotherapy. *Cancer Res*; 71(17); 5923–31. ©2011 AACR.

Introduction

The specific issue of hypoxia-induced radiation resistance has been acknowledged for more than 100 years and methods to describe and overcome the obstacle have occupied researchers in the field of radiotherapy ever since (1–3). Therapeutic initiatives such as hyperbaric oxygen (4), hypoxic radiosensitizers (5, 6), and hypoxic cytotoxins (7) to control tumor hypoxia have been promising, but the question still remains whether we are evaluating and directing the hypoxia-targeted therapy to the right patients.

Techniques to detect relevant tumor hypoxia have continuously evolved and the approaches have included both direct measurements in the tumor by an oxygen electrode (8, 9), infusion and detection of exogenous hypoxia tracers

[pimonidazole (10) and various PET-tracers (11–16)], or quantification of endogenous hypoxia markers expressed by the tumor cells under hypoxic conditions (17–19). Despite progression in these fields, no common treatment strategy and identification approach about hypoxia in tumors has yet been implemented in a clinical setting.

In this study, we aimed at generating a method for characterizing the hypoxic status of a tumor based on quantifying the gene expressions of hypoxia-responsive and hypoxia-specific genes within the tumor biopsy, and furthermore generate a method that could improve the ability of individualizing treatment in accordance to such characterization. Thus, the experimental plan involved identifying specific hypoxia-induced genes responding with a significant increase in expression correlating to a radiobiological relevant oxygen level (20) that could additionally identify patients having benefit from hypoxic modification of radiotherapy. Such "hypoxia-regulated genes" have previously been suggested in the literature (21–23), but to our knowledge none of the developed hypoxia gene expression signatures (24–26) have yet shown to be predictive for beneficial treatment strategies and consequently implemented in the clinic.

To identify relevant genes for hypoxia classification, we have previously focused especially on the influence of hypoxia and pH on gene expression *in vitro* (27). From these studies, 29 genes characterized by being upregulated under hypoxic conditions and furthermore being independent of pH fluctuations

Authors' Affiliations: ¹Department of Experimental Clinical Oncology, Aarhus University Hospital and ²Bioinformatics Research Centre, Aarhus University, Aarhus C, Denmark

Note: Supplementary data for this article are available at Cancer Research Online (<http://cancerres.aacrjournals.org/>).

Corresponding Author: Kasper Toustrup, Department of Experimental Clinical Oncology, Aarhus University Hospital, Nørrebrogade 44, DK-8000 Aarhus C, Denmark. Phone: 45-8949-2620; Fax: 45-8619-7109; E-mail: kasper@oncology.dk

doi: 10.1158/0008-5472.CAN-11-1182

©2011 American Association for Cancer Research.

were identified as potential classifier genes across a range of human squamous cell carcinoma cell lines. The identified genes were upregulated more than 2-fold under hypoxia in at least 4 of 5 cell lines. In addition, we chose to investigate and quantify the gene *CA9*, which has frequently been associated to hypoxia in the literature (refs. 28–30; Table 1).

We first validated the *in vivo* relevance of the *in vitro* identified genes in a xenograft study by applying the hypoxia radiotracer ¹⁸F-fluoroazomycin arabinoside (FAZA) in the detection and isolation of hypoxic and nonhypoxic tumor tissue. Following gene expression quantification, we compared the genetic response in the 2 areas to detect whether an upregulation in the hypoxic area could be registered. To proceed into the clinical setting, we then developed a hypoxia classifier on gene expressions quantified from hypoxia-eval-

uated human tumor biopsies. This classifier contained 15 of the *in vitro* identified hypoxia-responsive genes that could best discriminate between "more" and "less" hypoxic human head and neck squamous cell carcinomas (HNSCC; evaluated by oxygen electrode measurements). In an independent data set, where patients were randomized for either placebo or hypoxic modification in combination with radiotherapy, we finally evaluated whether the developed 15-gene hypoxia classifier could identify patients with hypoxic tumors and thereby identify patients that would potentially benefit from hypoxic modification. Our findings indicate that with this strategy, it has been possible to develop a 15-gene hypoxia classifier, which attain both prognostic and predictive impact.

Materials and Methods

Biological material

In vitro experiments were based on human squamous cell carcinoma cell lines UTSCC5, UTSCC14, UTSCC15 [oral carcinoma, unknown human papilloma virus (HPV) status, established by Dr. Reidar Grenman, University of Turku, Finland, obtained from Dr. Michael Baumann], FADU_{DD} (a subline of FaDu, an undifferentiated hypopharyngeal carcinoma, HPV-negative, obtained from Dr. Michael Baumann), and SiHa (uterine cervix carcinoma, HPV-positive, obtained from the American Type Culture Collection). Xenograft tumors for *in vivo* validation were generated with cell lines of UTSCC33 (oral carcinoma, unknown HPV status, established by Dr. Reidar Grenman, University of Turku, Finland, obtained from Dr. Michael Baumann), FADU_{DD}, and SiHa. None of the cell lines have been tested and authenticated. The hypoxia classifier was generated from 58 head and neck cancer biopsies archived as formalin-fixed and paraffin-embedded samples (FFPE). The oxygen status of these tumors had previously been evaluated in accordance to the relative number of oxygen electrode measurements less than 2.5 mm Hg in their metastatic lymph nodes (9, 31, 32). To test the prognostic and predictive impact of the developed classifier, we isolated mRNA from 326 accessible archival supraglottic larynx or pharynx tumor samples (FFPE) from the randomized, double-blinded DAHANCA 5 trial (6). Gene expression could be quantified in 323 samples, and these were individually classified as either "more" or "less" hypoxic. In the original study, 414 tumors had been randomized to either placebo or hypoxic modification with nimorazole [4-[2-(5-nitro-1*H*-imidazol-1-yl)ethyl]morpholine] in conjunction with conventional radiotherapy (62–68 Gy, 2 Gy/tx, 5 fx/wk). Those treated with nimorazole experienced an improved outcome in comparison with those treated with placebo. There was no significant differences in terms of patient and tumor characteristics (N- and T-stage, tumor site, tumor differentiation, age, gender, HPV status) and locoregional tumor failure between the 91 patients where RNA was not accessible and the 323 patients included in the present analysis (data not shown).

Identifying hypoxia-responsive pH-independent genes

The subjected genes were selected from the data from a previously published *in vitro* study, where the above-mentioned cell lines were exposed to different oxygen concentrations

Table 1. Hypoxia-responsive genes

<i>In vitro</i> derived genes	Included in hypoxia classifier	Function
<i>ADM</i>	ADM	Stress response
<i>AK3L1</i>		Nucleotide metabolism
<i>ALDOA</i>	ALDOA	Glucose metabolism
<i>ANKRD37</i>	ANKRD37	Protein–protein interactions
<i>ARRDC3</i>		Cell surface metabolism
<i>BNIP3</i>	BNIP3	Apoptosis
<i>BNIP3L</i>	BNIP3L	Apoptosis
<i>C3orf28</i>	C3orf28	Unknown
<i>C18orf19</i>		Unknown
<i>CCNG2</i>		Cell cycle regulation
<i>EGLN1</i>		Regulation of HIF-1 activity
<i>EGLN3</i>	EGLN3	Regulation of HIF-1 activity
<i>ERO1L</i>		Oxidoreductase
<i>FOSL2</i>		Cell proliferation
<i>GPI</i>		Glucose metabolism
<i>HIG2</i>		Stress response
<i>IGFBP3</i>		Cell proliferation
<i>JMJD1A</i>		Histone demethylase
<i>KCTD11</i>	KCTD11	Apoptosis
<i>LOC401152</i>		Unknown
<i>LOX</i>	LOX	Extracellular-matrix metabolism
<i>NDRG1</i>	NDRG1	Stress response
<i>P4HA1</i>	P4HA1	Extracellular-matrix metabolism
<i>P4HA2</i>	P4HA2	Extracellular-matrix metabolism
<i>PDK1</i>	PDK1	Energy metabolism
<i>PFKFB3</i>	PFKFB3	Glucose metabolism
<i>RORA</i>		Unknown
<i>SLC2A1</i>	SLC2A1	Glucose metabolism
<i>SLC6A8</i>		Glucose metabolism
<i>CA9</i> ^a		pH regulation

^aGene based on previous studies.

and pH levels (7.5 or 6.3; ref. 27). Gene expression was analyzed with microarray (Affymetrix–Human Genome U133 Plus 2.0 Array). In addition, the expression of the pH-dependent gene CA9 was evaluated. (Fig. 1A).

Hypoxia tracer and isolation of hypoxic xenograft tissue

In autoradiographic studies of xenograft tumors, FAZA was used as exogenous tracer revealing hypoxic tumor areas (<10 mm Hg; ref. 33). Immediately after cryosection of the excised tumor, autoradiography was carried out. This procedure was carried out at –20°C to minimize degradation of mRNA. By demarcating FAZA-positive areas (H) and FAZA-negative areas (N) from the autoradiography a computer-assisted (ImageGauge) 1:1 template was made to describe the hypoxic status inside the tumor. Guided by hematoxylin and eosin (H&E) staining of every fifth section (Fig. 1B), necrotic areas were avoided if possible and the demarcated areas were dissected. Tissue from multiple corresponding sections, but

representing each area, was pooled to achieve tissue for quantitative PCR (qPCR) quantification. Every fifth tumor section was left in total (M) before RNA extraction, cDNA preparation, and qPCR. All sections were preserved in RNA-later-ICE at –80°C prior to dissection.

Gene expression quantification

RNA from fresh-frozen tissue was extracted by using RNeasy-kit (Qiagen) according to the manufacturer's instructions. RNA from FFPE tumor biopsies was extracted by using a fully automated, bead-based RNA isolation procedure (34). cDNA was generated by using the High Capacity cDNA Archive kit (Applied Biosystems; ABI) and gene expression was quantified by using qPCR. cDNA based on FFPE samples was preamplified according to the manufacturer's details (TaqMan PreAmp, ABI) before real time qPCR. To detect transcripts of interest, TaqMan Gene Expression assay (ABI) was used for all potential classifier and reference genes




Figure 1. Identifying and validating hypoxia-responsive and pH-independent genes. A, *in vitro* derived genes characterized by hypoxia-induced upregulation and insensitivity to pH fluctuations (except CA9). B and C, H&E and autoradiographic presentation of hypoxia tracer FAZA distribution in xenograft tumor, tracer-positive area resembling hypoxic tumor tissue (H), tracer-negative area resembling nonhypoxic tumor tissue (N), total section resembling a heterogeneous mix of hypoxic and nonhypoxic tumors tissue (M). Autoradiographic image has been optimized to enhance visualization of hypoxic areas. D, fold upregulation in hypoxic tumor area (H) compared with nonhypoxic tumor area (N). E, fold upregulation in total heterogeneous tumor section (M) compared with nonhypoxic tumor tissue (N).

Downloaded from <http://aacrjournals.org/cancerres/article-pdf/71/17/5923/2659366/5923.pdf> by guest on 01 July 2022

(Supplementary Table S1). Reactions were carried out on an ABI Prism 7900 Sequence Detector (ABI) and in duplicate. Seven potential reference genes were analyzed: ACTR3, CHCHD1, NDFIP1, SPCS2, and TMEM85 were selected on the basis of our previous *in vitro* results (27); RPL37A and TFRC have previously been described (35, 36). The geNORM application available in RealTime Statminer (Intergromics) was used on the training set of 58 HNSCC samples, and 3 optimal reference genes (RPL37A, ACTR3, and NDFIP1) were selected for normalization. Data were analyzed by using Real-Time Statminer (Intergromics) and ΔC_t values were generated by normalizing to the geometric mean of the 3 reference genes. When analyzing FFPE samples, Ct values more than 35 or with an SD more than 0.3 were dismissed and interpreted as empty wells. Gene expression levels were quantified as $2^{-\Delta C_t}$ and log2-transformed before building the classifier.

Statistical analyses

Gene expression in the H, N, and M areas of the xenograft tumors were compared with Wilcoxon's signed rank analysis.

The prognostic impact of the 15-gene hypoxia classifier was evaluated on the placebo group of the DAHANCA 5 data set. This subgroup had been treated with radiotherapy alone (6). The predictive impact for hypoxic modification with nimorazole in conjunction with radiotherapy was evaluated by comparing the response to placebo or nimorazole among the groups classified as having "more" or "less" hypoxic tumors, respectively. A multivariable Cox proportional hazard analysis was used to evaluate the importance of independent tumor characteristics and treatment, with respect to the risk of locoregional failure. All patients were observed for at least 5 years or until death. Follow-up was completed as part of the original study. End point in the evaluation of the classifier was cumulative incidence of locoregional tumor failure defined as persistence or recurrence of the disease in the primary tumor (T site) or regional lymph nodes (N site) after radiotherapy and compared at 5 years. Death within 3 years after finalized treatment and without failure was considered a competing risk in the analysis (37). Statistical analyses were carried out with STATA 10 software. All *P* values are 2-sided with a level of significance at 5%.

Results

Suggested *in vitro* derived hypoxia-responsive genes are upregulated in hypoxic areas of *in vivo* xenograft tumors

To confirm the *in vivo* hypoxia specificity of the 30 genes, subcutaneous xenograft tumors in nude mice were established from 3 cell lines of human squamous cell carcinoma, of which 2 were used in the *in vitro* experiments. Before excision of the evolved tumor, mice were administered with the hypoxia tracer FAZA (33) which allowed *ex vivo* visualization of hypoxic tumor areas by autoradiography. A computer-assisted 1:1 template of demarcated FAZA-positive and FAZA-negative areas was generated from the autoradiography to guide the dissection of hypoxic and nonhypoxic tumor tissue (Fig. 1B and C). Tissue was isolated and gene expression


was quantified from each area, respectively. A Wilcoxon's signed rank analysis of the intratumor variability of gene expression measured with quantitative real-time reverse transcriptase PCR showed that all the suggested genes were significantly upregulated in hypoxic tumor areas (H) compared with nonhypoxic tumor areas (N; Fig. 1D). To mimic the clinical scenario where biopsies may include both well-oxygenated and hypoxic areas, we also compared the gene expression from nonhypoxic tumor areas with the gene expression in total neighbor sections (M) that represented more heterogeneous tissue material. With this, we expected to verify whether the hypoxia-induced upregulation would be traceable in terms of gene expression, irrespective of being quantified from a mix of both hypoxic and nonhypoxic tumor areas. We found all but 3 genes to be significantly upregulated (Fig. 1E), which supported their potential role as hypoxic markers.

Generation of a hypoxia classifier with prognostic impact included 15 hypoxia-responsive genes

Identification of the most informative genes for relevant hypoxia classification in human biopsies was carried out by quantifying gene expression in 58 head and neck cancer biopsies that had previously been hypoxia evaluated and ranked in accordance to oxygen electrode measurements in their metastatic neck nodes (9, 31, 32). In the effort of building the hypoxia classifier we separated and categorized the 58 tumors constituting the training set into a "more" hypoxic group containing the 10 tumors with the highest frequency of low oxygen electrode measurements and a "less" hypoxic group containing the remaining 48 tumors (Fig. 2A). With this split of the hypoxia-ranked tumors, we obtained 2 groups with the largest possible distance between mean gene expression levels among the groups and thereby the greatest discrimination in terms of gene expression. In short, the separation of the tumors into these 2 groups was determined by the ratio of between to within variations (*B/W*) in expression levels (see Supplementary Data on classification). We obtained the highest *B/W* ratios when the "more" hypoxic group consisted of the 10 most hypoxic tumors (Fig. 2B). Subsequently, an independent tumor would be classified as belonging to the predefined group ("more" or "less" hypoxic), where the distance from the gene expression level of the independent tumor and to the mean gene expression level of the predefined group was lowest (Supplementary Data on classification; Supplementary Table S2).

We then determined the number of genes to constitute the most optimal classifier. By use of a "leave one out" cross-validation approach (38), each sample from the training set was classified, one by one, as belonging to either of the 2 groups. The classification was based on all samples from the training set, excluding the sample being classified. Each of the 58 samples was then classified with combinations of the 30, 29, 28, and so on best separating genes. We found that a combination of 15 genes was optimal to classify the highest number of tumors into the same group as they were predefined into (Fig. 2C). As the final classifier, we chose the 15 candidate genes (Table 1) that were present with the highest frequency in the 58 "leave one out" classifications with a 15-gene classifier

Figure 2. Development and evaluation of the 15-gene hypoxia gene expression classifier. A, the predefined "more" and "less" hypoxic tumors based on hypoxia evaluation with oxygen electrode in metastatic lymph nodes. B, basis for the predefined grouping was founded on the most optimal ability to discriminate among the predefined groups, in terms of gene expression (*B/W* ratio). C, number of genes included in the classifier and the ability to classify tumor samples into the same group as they were predefined into, in the "leave one out" (LOO) cross-validation analysis. D, the most frequently present genes in a 15-gene hypoxia classifier. E, cumulative incidence of locoregional tumor failure in 156 independent head and neck cancer patients treated with conventional radiotherapy alone and separated into "more" and "less" hypoxic tumors by the 15-gene hypoxia classifier.



(Fig. 2D). To verify the prognostic relevance of the developed 15-gene hypoxia classifier, we categorized the 156 HNSCC biopsies from patients in the placebo group of the DAHANCA 5 trial as either "more" or "less" hypoxic. These patients had been treated with conventional radiotherapy and without hypoxic modification. The prognostic value is illustrated in Figure 2E, where patients categorized as having "more" hypoxic tumors suffered a significantly higher cumulative incidence of locoregional failure at 5 years as compared with patients categorized as "less" hypoxic (79% vs. 54%, $P = 0.001$).

The 15-gene hypoxia classifier predicts for hypoxic modification of radiotherapy with the radiosensitizer nimorazole

To test the classifiers potential for predicting which tumors could benefit from hypoxic modification of radiotherapy with nitroimidazoles, we applied the 15-gene classifier to 323 HNSCC biopsies from patients enrolled in the DAHANCA 5 trial. These patients had been randomized to either placebo or hypoxic modification with nimorazole in conjunction with conventional radiotherapy (6). Overall, the hypoxia classifier

Downloaded from http://aacrjournals.org/cancerres/article-pdf/71/17/5923/2659366/5923.pdf by guest on 01 July 2022

categorized 114 tumors (35%) as "more" hypoxic and 209 tumors (65%) as "less" hypoxic. In the group classified as "more" hypoxic (Fig. 3A), those treated with nimorazole in conjunction with radiotherapy carried a significantly reduced cumulative incidence of locoregional tumor failure after 5 years when compared with those treated with placebo and radiotherapy (46% vs. 79%, $P = 0.0001$). In the group classified as "less" hypoxic (Fig. 3B), we observed a uniform prognosis in




Figure 3. Prognostic and predictive impact of the 15-gene hypoxia gene expression classifier. A, cumulative incidence of locoregional tumor failure in the group categorized as having "more" hypoxic tumors randomized for placebo or nimorazole in conjunction with radiotherapy. B, cumulative incidence of locoregional tumor failure in the group categorized as having "less" hypoxic tumors randomized for placebo or nimorazole in conjunction with radiotherapy.

terms of cumulative incidence of locoregional tumor failure (46% vs. 54%, $P = 0.28$), irrespective of whether the patient had been treated with nimorazole or placebo in conjunction with the radiotherapy. This indicated a beneficial effect of additive treatment with nimorazole that was restricted to those tumors classified as "more" hypoxic. A Cox proportional hazards analysis for risk of locoregional failure was carried out. The following parameters were included in the model: 15-gene classification ("more" vs. "less" hypoxic), nodal status (N-positive vs. N-negative), tumor stage (T3-4 vs. T1-2), hypoxic modification (nimorazole vs. placebo), HPV status (p16-positive vs. p16-negative), gender (male vs. female), and age (<60 vs. ≥ 60). The 15-gene classifier was found to have independent prognostic importance with an HR of 1.41 (95% CI, 1.03–1.94). A test for interaction showed that the response to nimorazole was significantly different in the "more" hypoxic tumors compared with the response in the "less" hypoxic tumors ($P = 0.003$). In a separate multivariate analysis, nimorazole was an independent factor associated with good prognosis in "more" hypoxic tumors (HR = 0.42; 95% CI, 0.25–0.68), whereas there was no significant effect of hypoxic modification with nimorazole in "less" hypoxic tumors (HR = 0.98; 95% CI, 0.67–1.44).

Discussion

In principle, there are at least 3 different methods to measure hypoxic status of a tumor: the physical approach, with an oxygen sensing electrode inserted into the tumor (39); a metabolic approach with preinjection and visualization of metabolically bound exogenous hypoxia tracers (10, 14, 33); or the more biology-driven approach characterized by the measurement of one or more endogenous genes being expressed under hypoxic conditions in the tumor (17, 28). Despite negative influence of hypoxia on the outcome of HNSCC after radiotherapy and despite evidence that modification of hypoxia can benefit the patients with hypoxic tumors (3, 6), such methods for pretherapeutic hypoxic tumor evaluation have not yet been implemented in the clinical setting. This is probably due to an understandable combination of disadvantages either in the form of physical inconveniences, need for preinjection of tracer, or a lack of sensitivity or specificity of the hypoxia markers (17). In this project we tried to apply the advantages of 2 of these previously established methods to measure hypoxia to refine and improve the third approach into a more clinically relevant and applicable form. Thus, we developed a hypoxia gene expression classifier enabling us to characterize an independent tumor as either "more" or "less" hypoxic, based on the quantification of hypoxia-responsive genes in the tumor biopsy.

The initially suggested potential classifier genes were characterized by being upregulated under hypoxic conditions and furthermore independent of pH fluctuations in the previous *in vitro* studies (27). The pH parameter was included as studies have shown that hypoxia-induced genes can also be regulated by other factors such as inflammation and pH fluctuations (17, 36, 40). Therefore, independency to one or more of these

factors could hypothetically improve the hypoxia specificity of the gene in question. To improve the clinical applicability and the choice of potentially predictive genes contained in a hypoxia-specific signature/classifier, we aimed at identifying hypoxia-induced and pH-independent genes. In addition to the pH-independent genes, we also chose to evaluate the pH-dependent gene *CA9* due to its frequent linkage to hypoxia in the literature (41–43).

At first, we verified that the genes being upregulated under hypoxic *in vitro* conditions were also upregulated in hypoxic areas of *in vivo* xenograft tumors (Fig. 1D). Furthermore the hypoxia-induced gene expression could also be measured from total xenograft sections which resembled tumor biopsies (Fig. 1E). We therefore believe that these genes can be used as indicators of clinically relevant hypoxia. We also registered that although 27 of the genes were significantly upregulated in the total sections compared with the nonhypoxic tumor tissue, the magnitude of upregulation varied considerably. Thus, a fraction of the suggested genes probably carried more hypoxia-specific information than all of the genes together. In a recent study by Marotta and colleagues (22), a comparable xenograft approach was applied in the description of *in vitro* versus *in vivo* hypoxia-responsive genes in a single gliosarcoma model. Few genes were common to the 2 growth conditions, and in general they found striking differences between the global *in vitro* and *in vivo* hypoxic mRNA profiles. In contrast to Marotta and colleagues, we did not aim at identifying a new set of *in vivo* generated hypoxia-responsive genes through an explorative supervised cDNA microarray analysis in a xenograft study, but used it as an *in vivo* verification of the hypoxia-induced upregulation already observed in the previous *in vitro* studies. Furthermore, the genes from our *in vitro* studies were selected on the basis of several different cell lines, and this probably explains why we in general observe a good correlation between our *in vitro* and *in vivo* settings. Interestingly, 13 of the 30 suggested hypoxia-responsive genes included in our study were also identified either in the *in vitro* or the *in vivo* studies from the Marotta and colleagues. This supports the idea that common hypoxia-induced genes can be used to evaluate hypoxia in different tumor sites (26).

In contrast to previous studies on hypoxia gene expression classifiers, we wanted to build a classifier based on the hypoxic status of the tumors. We therefore developed the final 15-gene classifier in a training set of 58 HNSCC tumors that were evaluated and ranked according to the number of low oxygen-electrode measurements of their metastatic neck nodes (31, 32, 44). We also wished to develop a robust classifier that can be used routinely to classify individual FFPE tumor biopsies. Compared with the previously published hypoxia signatures (22, 24–26) we identified some genes that are in common. In the most comprehensive study, Buffa and colleagues used a network-based approach involving both coexpression networks and gene set enrichment analysis to identify a gene expression signature that correlates with prognosis across different tumor sites (26). That there is some overlap between the genes identified by these very different approaches supports the use of gene expression as a global marker for

hypoxia. However, because of the difference between the approaches, we would also expect to find genes that are not in common. First, we did not develop the classifier on the basis of its prognostic value, but solely on the association with hypoxic status in the tumor. Second, some of the coexpression networks in the network-based approach include *CA9* (25, 26). Although *CA9* failed in our *in vitro* analysis which generally excluded pH-dependent genes, we chose to include it in the analysis. In the xenograft study, *CA9* was indeed upregulated in hypoxic areas consistent with the findings by Marotta and colleagues (22). However, *CA9* was not correlated to the hypoxic status of the tumors in the training set, and is not among the genes in the final 15-gene classifier. Finally, we have specifically focused on test genes and reference genes that can be measured robustly in FFPE samples and where gene expression measurements in an unknown sample can be used directly to classify the tumor in a clinical setting. Although the samples in the validation set were 20 to 24 years old, we could successfully classify 323 of 326 tumors. Whether these exact classification levels can be directly applied to tumors of other cellular origin still remains to be examined.

The relevance of the classification levels in HNSCC was tested when classifying the 323 patients from the DAHANCA 5 trial as either "more" or "less" hypoxic. This validation set was unique as both prognostic and predictive evaluation was possible. We verified the prognostic relevance of the classifier by focusing on the outcome of the classified tumors in the placebo group. These tumors were treated with radiotherapy alone. We observed a significantly poorer outcome of those tumors classified as "more" hypoxic, when compared with the "less" hypoxic tumors (Fig. 2E). We believe this difference can be explained by a more pronounced resistance to radiotherapy in the "more" hypoxic tumors, thus a less efficient treatment response.

By including those randomized for hypoxic modification in the analysis, we also showed the predictive impact of the classifier. Those tumors classified as "more" hypoxic responded significantly better to the radiosensitizer nimorazole than compared with those classified as "less" hypoxic (Fig. 3A and B). This was confirmed in a multivariate analysis. Thus, we conclude that when quantifying the expression of hypoxia-induced genes in the tumor biopsy, the classifier identifies a subgroup of candidate HNSCC patients for hypoxic modification of radiotherapy. Therefore, the 15-gene hypoxia classifier attains both prognostic and predictive potential and suggests that hypoxic modification of radiotherapy should only be tailored to a subgroup of patients with gene expression classified "more" hypoxic tumors.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

Cell lines were obtained courtesy of Dr. Reidar Grenman and Dr. Michael Baumann. We thank I.M. Thuesen, B. Kierkegaard, A. Baden, and M. Johansen for technical assistance.

Grant Support

The work was supported by grants from the Danish Cancer Society, the Danish Medical Research Council, the Danish Council for Strategic Research, the EC FP7 project METOXIA, and CIRRO—the Lundbeck Foundation Centre for Interventional Research in Radiation Oncology.

References

- Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. *Radiother Oncol* 2005;77:18–24.
- Overgaard J. Hypoxic radiosensitization: adored and ignored. *J Clin Oncol* 2007;25:4066–74.
- Overgaard J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck—a systematic review and meta-analysis. *Radiother Oncol* 2011[Epub ahead of print].
- Mayer R, Hamilton-Farrell MR, van der Kleij AJ, Schmutz J, Granstrom G, Sicko Z, et al. Hyperbaric oxygen and radiotherapy. *Strahlenther Onkol* 2005;181:113–23.
- Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. *Oncol Res* 1994;6:509–18.
- Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. *Radiother Oncol* 1998;46:135–46.
- Brown JM. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. *Br J Cancer* 1993;67:1163–70.
- Nordsmark M, Bentzen SM, Overgaard J. Measurement of human tumour oxygenation status by a polarographic needle electrode. An analysis of inter- and intratumour heterogeneity. *Acta Oncol* 1994;33:383–9.
- Nordsmark M, Overgaard J. Tumor hypoxia is independent of hemoglobin and prognostic for loco-regional tumor control after primary radiotherapy in advanced head and neck cancer. *Acta Oncol* 2004;43:396–403.
- Raleigh JA, Chou SC, Arteel GE, Horsman MR. Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. *Radiat Res* 1999;151:580–9.
- Kaanders JH, Wijffels KI, Marres HA, Ljungkvist AS, Pop LA, van den Hoogen FJ, et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. *Cancer Res* 2002;62:7066–74.
- Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S, et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. *J Clin Oncol* 2006;24:2098–104.
- Mortensen LS, Buus S, Nordsmark M, Bentzen L, Munk OL, Keiding S, et al. Identifying hypoxia in human tumors: a correlation study between 18F-FMISO PET and the Eppendorf oxygen-sensitive electrode. *Acta Oncol* 2010;49:934–40.
- Gross M, Karbach U, Groebe K, Franko A, Mueller-Klieser W. Calibration of misonidazole labelling by simultaneous measurement of oxygen tension and labeling density in multicellular spheroids. *Int J Cancer* 1995;567–73.
- Evans SM, Hahn S, Pook DR, Jenkins WT, Chalian AA, Zhang P, et al. Detection of hypoxia in human squamous cell carcinoma by EF5 binding. *Cancer Res* 2000;60:2018–24.
- Isa AY, Ward TH, West CM, Slevin NJ, Homer JJ. Hypoxia in head and neck cancer. *Br J Radiol* 2006;79:791–8.
- Moon EJ, Brizel DM, Chi JT, Dewhirst MW. The potential role of intrinsic hypoxia markers as prognostic variables in cancer. *Antioxid Redox Signal* 2007;9:1237–94.
- Le QT, Courter D. Clinical biomarkers for hypoxia targeting. *Cancer Metastasis Rev* 2008;27:351–62.
- Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR. Plasma osteopontin, hypoxia, and response to the hypoxia sensitizer nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. *Lancet Oncol* 2005;6:757–64.
- Sørensen BS, Hao J, Overgaard J, Vorum H, Honore B, Alsner J, et al. Influence of oxygen concentration and pH on expression of hypoxia induced genes. *Radiother Oncol* 2005;76:187–93.
- Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, Le QT, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. *Nature* 2006;440:1222–6.
- Marotta D, Karar J, Jenkins WT, Kumanova M, Jenkins KW, Tobias JW, et al. In vivo profiling of hypoxic gene expression in gliomas using the hypoxia marker EF5 and laser-capture microdissection. *Cancer Res* 2011;71:779–89.
- Le QT, Harris J, Magliocco AM, Kong CS, Diaz R, Shin B, et al. Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03. *J Clin Oncol* 2009;27:4281–6.
- Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. *PLoS Med* 2006;3:e47.
- Winter SC, Buffa FM, Silva P, Miller C, Valentine HR, Turley H, et al. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. *Cancer Res* 2007;67:3441–9.
- Buffa FM, Harris AL, West CM, Miller CJ. Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. *Br J Cancer* 2010;102:428–35.
- Sørensen BS, Toustrup K, Horsman MR, Overgaard J, Alsner J. Identifying pH independent hypoxia induced genes in human squamous cell carcinomas in vitro. *Acta Oncol* 2010;49:895–905.
- Vordermark D, Brown JM. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance? *Strahlenther Onkol* 2003;179:801–11.
- Le QT, Kong C, Lavori PW, O'byrne K, Erler JT, Huang X, et al. Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. *Int J Radiat Oncol Biol Phys* 2007;69:167–75.
- Eriksen JG, Overgaard J. Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study. *Radiother Oncol* 2007;83:383–8.
- Nordsmark M, Overgaard J. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. *Radiother Oncol* 2000;57:39–43.
- Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. *Radiother Oncol* 1996;41:31–9.
- Busk M, Horsman MR, Jakobsen S, Bussink J, van der KA, Overgaard J. Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. *Eur J Nucl Med Mol Imaging* 2008;35:2294–303.
- Bohmann K, Hennig G, Rogel U, Poremba C, Mueller BM, Fritz P, et al. RNA extraction from archival formalin-fixed paraffin-embedded tissue: a comparison of manual, semiautomated, and fully automated purification methods. *Clin Chem* 2009;55:1719–27.
- Hennig G, Gehrman M, Stropp U, Brauch H, Fritz P, Eichelbaum M, et al. Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression. *Clin Chem* 2010;56:1845–53.

36. Sorensen BS, Alsner J, Overgaard J, Horsman MR. Hypoxia induced expression of endogenous markers in vitro is highly influenced by pH. *Radiother Oncol* 2007;83:362–6.
37. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD. A note on competing risks in survival data analysis. *Br J Cancer* 2004;91:1229–35.
38. Dyrskjot L, Thykjaer T, Kruhoffer M, Jensen JL, Marcussen N, Hamilton-Dutoit S, et al. Identifying distinct classes of bladder carcinoma using microarrays. *Nat Genet* 2003;33:90–6.
39. Doll CM, Milosevic M, Pintilie M, Hill RP, Fyles AW. Estimating hypoxic status in human tumors: a simulation using Eppendorf oxygen probe data in cervical cancer patients. *Int J Radiat Oncol Biol Phys* 2003;55:1239–46.
40. Helmlinger G, Yuan F, Dellian M, Jain RK. Interstitial pH and pO₂ gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. *Nat Med* 1997;3:177–82.
41. Ahlskog JK, Schliemann C, Marlind J, Qureshi U, Ammar A, Pedley RB, et al. Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours. *Br J Cancer* 2009;101:645–57.
42. Kaluz S, Kaluzova M, Liao SY, Lerman M, Stanbridge EJ. Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show? *Biochim Biophys Acta* 2009;1795:162–72.
43. Russell J, Carlin S, Burke SA, Wen B, Yang KM, Ling CC. Immunohistochemical detection of changes in tumor hypoxia. *Int J Radiat Oncol Biol Phys* 2009;73:1177–86.
44. Nordmark M, Eriksen JG, GebSKI V, Alsner J, Horsman MR, Overgaard J. Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. *Radiother Oncol* 2007;83:389–97.